Vertex Pharmaceuticals Incorporated Stock News

Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q4 2021 Results - Earnings Call Transcript

Vertex Pharmaceuticals press release (NASDAQ:VRTX): Q4 Non-GAAP EPS of $3.37 beats by $0.08.Revenue of $2.07B (+27.0% Y/Y) beats by $60M.

Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Rank and ESP are still a solid combination to predict earnings beats.

AbbVie will be releasing Phase 2 data for its experimental Cystic Fibrosis (CF) drugs that could potentially compete with Vertex's drugs. VRTX stock may move up or down, inversely related to the AbbVi

AFT is a closed end fund focusing on leveraged loans. The vehicle provides for a natural inflation hedge given the floating rate nature of the underlying loans.

Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.

All of them have tremendous growth prospects.

Six large-cap companies will report earnings next week. These are: TSLA, URI, FCX, VRTX, STLD and BRO.

BMO has upgraded shares of Vertex Pharmaceuticals based on recent promising data for VX-147, its candidate for the rare kidney condition focal segmental glomerulosclerosis.

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as ArcBest (ARCB), Advanced Micro Devices (AMD), AGCO Corporation (AGC

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.